These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32294777)

  • 21. [Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature].
    Desramé J; Duvic C; Bredin C; Béchade D; Artru P; Brézault C; Defuentes G; Poirier JM; Dourthe LM; Coutant G; Chaussade S; de Gramont A; Algayres JP
    Rev Med Interne; 2005 Mar; 26(3):179-88. PubMed ID: 15777580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy.
    Lhotta K; Kühr T; Rumpelt HJ; Wöll E; Thaler J; König P
    Am J Nephrol; 1999; 19(5):590-3. PubMed ID: 10575189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report.
    Serke S; Riess H; Oettle H; Huhn D
    Br J Cancer; 1999 Mar; 79(9-10):1519-21. PubMed ID: 10188900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hemolytic uremic syndrome following gemcitabine treatment].
    Bourquin V; Guinand A; Haenni C; Giovannini M; Delouche D; Dettwiler S; Moll S
    Rev Med Suisse; 2008 Apr; 4(154):1056-61. PubMed ID: 18557535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemolytic-uremic syndrome caused by gemcitabine.
    Nackaerts K; Daenen M; Vansteenkiste J; Vandevelde A; Van Bleyenbergh P; Demedts M
    Ann Oncol; 1998 Dec; 9(12):1355. PubMed ID: 9932169
    [No Abstract]   [Full Text] [Related]  

  • 26. Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin.
    Lewin SN; Mutch DG; Whitcomb BP; Liapis H; Herzog TJ
    Gynecol Oncol; 2005 Apr; 97(1):228-33. PubMed ID: 15790464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine-induced hemolytic uremic syndrome: a case report.
    Brodowicz T; Breiteneder S; Wiltschke C; Zielinski CC
    J Natl Cancer Inst; 1997 Dec; 89(24):1895-6. PubMed ID: 9414181
    [No Abstract]   [Full Text] [Related]  

  • 28. Gemcitabine-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
    Held-Warmkessel J
    Oncol Nurs Forum; 2014 Sep; 41(5):551-3. PubMed ID: 25158661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine.
    Flombaum CD; Mouradian JA; Casper ES; Erlandson RA; Benedetti F
    Am J Kidney Dis; 1999 Mar; 33(3):555-62. PubMed ID: 10070921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
    Kozuch P; Petryk M; Bruckner HW
    Hematol Oncol Clin North Am; 2002 Feb; 16(1):123-38. PubMed ID: 12063823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine-induced hemolytic uremic syndrome mimicking scleroderma renal crisis presenting with Raynaud's phenomenon, positive antinuclear antibodies and hypertensive emergency.
    Yamada Y; Suzuki K; Nobata H; Kawai H; Wakamatsu R; Miura N; Banno S; Imai H
    Intern Med; 2014; 53(5):445-8. PubMed ID: 24583433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.
    Gross M; Hiesse C; Kriaa F; Goldwasser F
    Anticancer Drugs; 1999 Jul; 10(6):533-6. PubMed ID: 10885900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemolytic uremic syndrome after chemotherapy with gemcitabine and taxotere: a case report.
    Citarrella P; Gebbia V; Teresi M; Miceli S; Sciortino G; Vaglica M; Pizzardi N; Palmeri S
    Anticancer Res; 2002; 22(2B):1183-5. PubMed ID: 12168922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report.
    Bharthuar A; Egloff L; Becker J; George M; Lohr JW; Deeb G; Iyer RV
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):177-81. PubMed ID: 19116715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haemolytic uraemic syndrome associated with gemcitabine.
    Moya-Horno I; Querol Niñerola R; Bonfill Abella T; Dalmau Pórtulas E; Gallardo-Díaz E; Saigí Grau E; Pericay Pijaume C
    Clin Transl Oncol; 2010 May; 12(5):381-3. PubMed ID: 20466623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review.
    Ritchie GE; Fernando M; Goldstein D
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):1-7. PubMed ID: 27497971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
    Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
    Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?
    Gore EM; Jones BS; Marques MB
    J Clin Apher; 2009; 24(5):209-14. PubMed ID: 19816959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.
    Rabinowits G; Herchenhorn D; Rabinowits M; Weatge D; Torres W
    Anticancer Drugs; 2003 Sep; 14(8):665-8. PubMed ID: 14501391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hemolytic-uremic syndrome complicating a long-term treatment with gemcitabine. Report of a case and review of the literature].
    Dilhuydy MS; Delclaux C; Pariente A; De Precigout V; Aparicio M
    Rev Med Interne; 2002 Feb; 23(2):189-92. PubMed ID: 11876063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.